Nanotechnology company AnteoTech has reported positive results from studies to assess the accuracy of its Covid-19 (SARS- CoV2) Antigen Rapid Test.
The test is a disposable immunochromatographic test for the detection of SARS-CoV-2 nucleocapsid antigen in specimens, allowing the diagnosis of Covid-19 in the early stages of infection.
Brisbane-based AnteoTech reported a clinical study of its test conducted by the Victorian Infectious Diseases Reference Laboratory, which is part of the Peter Doherty Institute for Infection and Immunity.
In total 444 identified nasopharyngeal samples were analysed or which 184 were clinically diagnosed as positive for SARS-CoV-2 and 260 as negative.
The AnteoTech test showed an overall sensitivity rate to the presence of the virus of 97.3 per cent and a specificity of 99.6 per cent.
There was no observed cross-reactivity with other common corona viruses or selected bacteria, suggesting the test is very specific and produces few false positives.
The results of the study are part of an application for European CE mark approval.
Subscribe to our free @AuManufacturing newsletter here.